A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group
| Autor: | Judith M Bliss, H Cortes-Funes, Jacques Wils, G Beretta, R C Coombes, C E D Chilvers, D Amadori, A Villar-Grimalt, P S Schein, A Rutten |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Nausea medicine.medical_treatment Mitomycin Adenocarcinoma Gastroenterology law.invention Mitomycins Randomized controlled trial law Stomach Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Multicenter Studies as Topic Doxorubicin Prospective Studies Randomized Controlled Trials as Topic Chi-Square Distribution business.industry Significant difference Cancer Middle Aged medicine.disease Combined Modality Therapy United States Surgery Europe Survival Rate Oncology Fluorouracil Vomiting Regression Analysis Female medicine.symptom business Adjuvant medicine.drug Follow-Up Studies |
| Zdroj: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 8(8) |
| ISSN: | 0732-183X |
| Popis: | Three hundred fifteen patients with operable gastric cancer were randomized to receive fluorouracil, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and mitomycin (FAM) or no adjuvant treatment between September 1981 and July 1984. After excluding ineligible patients, 281 patients are included in this analysis. Treatment was moderately well tolerated by the majority of patients, the common side effects being nausea and vomiting (58%) and alopecia (57%). Three possible treatment-related deaths were seen, all due to cardiac failure. At median follow-up of 68 months, 164 patients have died, 73 in the treated arm and 91 in the control arm. There was no significant difference in disease-free or overall survival between the two arms of the study (P = 0.21). There is some evidence that patients with more advanced carcinoma (T3-T4) derived some benefit from treatment (P = 0.04). The interpretation of this finding must take into account that all subgroups were defined retrospectively, and this could, therefore, be a chance finding. We conclude that adjuvant chemotherapy as given in this trial is not indicated as routine treatment in operable gastric cancer, but that further evaluation in stage T3-T4 patients is warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|